MSD Germany has appointed Dr Susanne Fiedler as CEO to take over from Hanspeter Quodt, who steps after seven years in the post.
Dr Fielder first joined the German operations of Merck & Co in 1997, when she took up a role in market research.
She then moved to market, initially as a product manager and later as a marketing manager and then a business unit head with responsibility for a number of MSD products.
Since then Dr Fielder has served in the US, where MSD operates at Merck & Co, as global brand leader for the diabetes treatments Januvia and Janumet, before taking up a Sydney-based role as managing director of MSD Australia and New Zealand.
She will officially take on her new role on 1 February, when Quodt moves to a new European level position.
AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.
Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.
Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.